AstraZeneca (AZN) Stock Buyback History
TTM buyback yield 0.07% · Shareholder yield (TTM) 0.07%.
AZN
TTM buyback yield
0.07%
Shareholder yield (TTM)
0.07%
5Y share count change
19.0%
TTM buyback spend
$211.58M
SBC coverage (TTM)
N/A
YoY change in spend
N/A
5Y CAGR of spend
N/A
Peak year (2011)
$6.01B
Cumulative spend
$29.99B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- AstraZeneca (AZN) repurchased about $211.58M of stock over the trailing twelve months.
- Diluted share count is up 19.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM repurchases used about 5% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $719.66M | $0.00 | $719.66M | 1.56B | -0.1% | 0.26% |
| 2024 | $0.00 | $0.00 | $0.00 | 1.56B | 0.1% | — |
| 2023 | $0.00 | $579.00M | −$579.00M | 1.56B | 0.1% | — |
| 2022 | $0.00 | $619.00M | −$619.00M | 1.56B | 9.3% | — |
| 2021 | $0.00 | $615.00M | −$615.00M | 1.43B | 8.7% | — |
| 2020 | $0.00 | $277.00M | −$277.00M | 1.31B | 0.9% | — |
| 2019 | $0.00 | $259.00M | −$259.00M | 1.30B | 2.7% | — |
| 2018 | $0.00 | $0.00 | $0.00 | 1.27B | 0.0% | — |
| 2017 | $0.00 | $0.00 | $0.00 | 1.27B | 0.1% | — |
| 2016 | $0.00 | $0.00 | $0.00 | 1.27B | 0.1% | — |
| 2015 | $0.00 | $0.00 | $0.00 | 1.26B | 0.1% | — |
| 2014 | $0.00 | $0.00 | $0.00 | 1.26B | 0.8% | — |
| 2013 | $0.00 | $0.00 | $0.00 | 1.25B | -0.8% | — |
| 2012 | $2.63B | $0.00 | $2.63B | 1.26B | -7.5% | 4.47% |
| 2011 | $6.01B | $0.00 | $6.01B | 1.37B | -5.5% | 9.90% |
| 2010 | $2.60B | $0.00 | $2.60B | 1.45B | -0.3% | 3.98% |
| 2009 | $0.00 | $0.00 | $0.00 | 1.45B | -0.2% | — |
| 2008 | $610.00M | $0.00 | $610.00M | 1.45B | -3.0% | 1.03% |
| 2007 | $4.17B | $0.00 | $4.17B | 1.50B | -4.6% | 6.68% |
| 2006 | $4.15B | $0.00 | $4.15B | 1.57B | -3.0% | 5.10% |
| 2005 | $3.00B | $0.00 | $3.00B | 1.62B | -3.3% | 3.91% |
| 2004 | $2.21B | $0.00 | $2.21B | 1.67B | -2.1% | 3.67% |
| 2003 | $1.11B | $0.00 | $1.11B | 1.71B | -1.5% | 1.38% |
| 2002 | $1.15B | $0.00 | $1.15B | 1.74B | -1.3% | 1.92% |
| 2001 | $1.08B | $0.00 | $1.08B | 1.76B | -0.6% | 1.33% |
| 2000 | $353.98M | $0.00 | $353.98M | 1.77B | -0.5% | — |
| 1999 | $183.00M | $0.00 | $183.00M | 1.78B | 90.2% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.93B | -1.8% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.95B | 0.4% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.95B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for AstraZeneca (AZN) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for AstraZeneca (AZN)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for AstraZeneca (AZN)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $719.66M | — | +$719.66M | ||
| 2024 | $0 | — | $0 | ||
| 2023 | $0 | — | $0 | ||
| 2022 | $0 | — | $0 | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | — | $0 | ||
| 2019 | $0 | — | $0 | ||
| 2018 | $0 | — | $0 | ||
| 2017 | $0 | — | $0 | ||
| 2016 | $0 | — | $0 | ||
| 2015 | $0 | — | $0 | ||
| 2014 | $0 | — | $0 | ||
| 2013 | $0 | -100.0% | -$2.63B | ||
| 2012 | $2.63B | -56.2% | -$3.38B | ||
| 2011 | $6.01B | +131.0% | +$3.41B | ||
| 2010 | $2.60B | — | +$2.60B | ||
| 2009 | $0 | -100.0% | -$610.00M | ||
| 2008 | $610.00M | -85.4% | -$3.56B | ||
| 2007 | $4.17B | +0.6% | +$23.00M | ||
| 2006 | $4.15B | +38.2% | +$1.15B | ||
| 2005 | $3.00B | +35.7% | +$789.00M | ||
| 2004 | $2.21B | +99.8% | +$1.10B | ||
| 2003 | $1.11B | -4.1% | -$47.00M | ||
| 2002 | $1.15B | +6.9% | +$74.00M | ||
| 2001 | $1.08B | +205.1% | +$726.02M | ||
| 2000 | $353.98M | +93.4% | +$170.98M | ||
| 1999 | $183.00M | — | +$183.00M | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | — | $0 | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | $0 | ||
| 1990 | $0 | — | — |
2025's annual buyback spend for AstraZeneca (AZN) came in at $719.66M.
Between 2011 and 2025, AstraZeneca buyback spend plunged 88.0%, falling from $6.01B to $719.66M.
The highest annual buyback spend of $6.01B was reported in 2011. The lowest in the available history was $0 in 1990.
Among 8 Healthcare peers, AstraZeneca (AZN) ranks 8th; the peer median for buyback spend is $3.55B.
AstraZeneca Buyback Spend 2025: $719.66M
AstraZeneca buyback spend in 2025 was $719.66M.
AstraZeneca Buyback Spend 2024: $0
AstraZeneca buyback spend in 2024 was $0.
AstraZeneca Buyback Spend 2023: $0
AstraZeneca buyback spend in 2023 was $0.
AstraZeneca Buyback Spend 2022: $0
AstraZeneca buyback spend in 2022 was $0.
AstraZeneca Buyback Spend 2021: $0
AstraZeneca buyback spend in 2021 was $0.
See more financial history for AstraZeneca (AZN).
Sector peers by buyback spend
Companies in the same sector as AstraZeneca, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Thermo Fisher Scientific (TMO) | $3.00B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: N/A.
Capital allocation mix
How AstraZeneca splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $4.22B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from AstraZeneca's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does AstraZeneca buy back its own stock?
Yes, AstraZeneca (AZN) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does AstraZeneca spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $211.58M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is AstraZeneca's buyback yield?
TTM buyback yield is about 0.07% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is AstraZeneca's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.07% combined (TTM-based where available).
Is AstraZeneca diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has AstraZeneca's share count changed?
Diluted weighted average shares changed by about 19.0% over roughly five fiscal years (annual income statement data).
What is AstraZeneca's buyback spend?
Latest reported buyback spend for AstraZeneca (AZN) is $211.58M (period ending March 31, 2026).
When did AstraZeneca buyback spend hit its highest annual value?
AstraZeneca buyback spend reached its highest annual value of $6.01B in 2011.
What was AstraZeneca buyback spend in 2024?
AstraZeneca (AZN) buyback spend in 2024 was $0.
What was AstraZeneca buyback spend in 2025?
AstraZeneca (AZN) buyback spend in 2025 was $719.66M.
Explore more
AZN Overview
Company profile, financial tools, and key metrics
AZN Revenue Counter
Earns $1,917 every second. See per minute, hour, and day.
AZN Earnings Counter
Earns $329.43 per second net profit. See per minute, hour, and day.
AZN Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
AZN What If Invested
What if you had invested $1,000? See historical returns from any date.
AZN How It Makes Money
Discover visual breakdown of $60.44B in revenue — where it comes from and where it goes.
AZN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AZN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AZN Daily Price Character
Steady · 49.4% historical win rate (green days). Streaks & record days.
AZN Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
AZN Dividend Profile
Yield: 1.71%. Safety: 6/8. See full history.
AZN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AZN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
AZN Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
AZN Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.